| 2/24/2022 | IG | New Issue: Bio-Rad details $1.2 billion two-part sale of notes due 2027, 2032
|
| 2/23/2022 | IG | New Issue: Bio-Rad sells $1.2 billion of notes in two parts due 2027, 2032
|
| 2/23/2022 | BKIG | Moody's gives Bio-Rad, notes Baa2
|
| 2/23/2022 | BKIG | Fitch assigns Bio-Rad notes BBB
|
| 2/23/2022 | IG | Bio-Rad to sell dollar senior notes via seven bookrunners
|
| 2/23/2022 | BKIG | S&P gives Bio-Rad notes BBB
|
| 8/20/2019 | BKIG | Fitch ups Bio-Rad to BBB
|
| 6/27/2019 | IG | S&P downgrades Apoteket
|
| 6/27/2019 | BKIG | Moody's upgrades Bio-Rad
|
| 4/18/2019 | BKIG | Fitch rates Bio-Rad revolver BBB-
|
| 7/27/2018 | BKIG | Fitch affirms Bio-Rad Laboratories
|
| 7/3/2018 | BKIG | Moody’s changes Bio-Rad view
|
| 5/29/2015 | BKIG | S&P: Bio-Rad business risk ‘fair’
|
| 7/17/2014 | BKHYIG | Moody’s lifts Bio-Rad to Baa3
|
| 4/9/2012 | BKHYIG | Moody's: Bio-Rad view positive
|
| 11/18/2011 | IG | Fitch affirms Bio-Rad
|
| 12/7/2010 | IG | S&P rates Bio-Rad notes BBB
|
| 12/6/2010 | IG | Market Commentary: IBM, CIBC, Carlisle, NAB among sellers in hot primary; AT&T, Verizon flat on downgrades
|
| 12/6/2010 | HYIG | New Issue: Bio-Rad sells $425 million 4.875% 10-year senior notes at Treasuries plus 200 bps
|
| 12/6/2010 | HYIG | Moody's rates Bio-Rad notes Ba1
|
| 12/6/2010 | HYIG | Fitch rates Bio-Rad, loans BBB-, notes BBB- and BB+
|
| 12/6/2010 | HYIGLM | Bio-Rad plans to redeem its $425 million 71/2%, 6 1/8% senior notes
|
| 12/6/2010 | IG | Bio-Rad Labs files automatic shelf registration for debt securities
|
| 4/30/2010 | HYIG | S&P upgrades Bio-Rad
|
| 4/23/2009 | IG | S&P: Bio-Rad outlook positive
|
| 1/14/2008 | BKHYIG | S&P raises Bio-Rad to investment grade
|
